Korea South
Deep Bio Inc. is a biotechnology startup headquartered in Korea South. Founded in 2015, the company has garnered attention for its innovative approach to addressing unmet medical needs. Deep Bio's flagship product, DeepDx®, leverages deep learning technology to offer pathologists fast, efficient, and reliable solutions aimed at improving the clinical workflow.
Primarily focusing on digital pathology, Deep Bio utilizes a convolutional neural network to process a vast array of needle biopsy images with the goal of developing a cutting-edge computer-aided detection and diagnosis system specifically tailored for prostate cancer.
The company recently achieved a significant milestone with its Series B investment secured on 09 March 2020. Although details regarding the investors are currently undisclosed, this round of funding is expected to propel Deep Bio's efforts in research and development, as well as market expansion.
With its pioneering approach and commitment to addressing critical medical challenges, Deep Bio Inc. is well-positioned to make a lasting impact in the biotechnology sector.
